Dyne Therapeutics (DYN) Director Jason Rhodes Sells Shares

What Happened Jason P. Rhodes, a director of Dyne Therapeutics (DYN), reported open-market sales of a total of 2,586,928 shares between Aug 13–14, 2026, generating aggregate proceeds of $65,184,895. Sales on Aug 13 totaled 426,412 shares at a weighted average price of $26.20 (proceeds $11,171,995; individual trade prices ranged ~$25.8788–$26.48). Sales on Aug 14 totaled 2,160,516 shares at a weighted average price of $25.00 (proceeds $54,012,900; individual trade prices ranged $25.00–$25.8916). These were dispositions (sales), not purchases.

Key Details

• Transaction dates: Aug 13, 2026 and Aug 14, 2026; Form 4 filed Aug 17, 2026 (appears timely).
• Shares sold: 2,586,928 total; proceeds ~$65,184,895.
• Prices: weighted averages $26.20 (Aug 13 sales) and $25.00 (Aug 14 sales); detailed per-transaction ranges provided in the filing.
• Footnotes of note:
  • Sales were made pursuant to a Rule 10b5-1 trading plan adopted July 13, 2026 (F1).
  • Price figures are weighted averages; the filing offers to provide per-price breakdowns on request (F2, F6).
  • Several blocks sold were held by Atlas Venture funds and related entities; Rhodes disclaims Section 16 beneficial ownership of those fund-held shares except to the extent of any pecuniary interest (F3–F5, F7).
• Shares owned after the transactions are not specified here; see the Form 4 for the reporting person's post-transaction holdings.

Context

• These are scheduled open-market sales under a 10b5-1 plan (a pre-arranged trading plan), which is commonly used by insiders to sell shares for liquidity and to avoid claims of trading on contemporaneous nonpublic information. Sales do not necessarily indicate any change in the insider's view of the company.